Isala Zwolle

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Heart failure2 trials
• Aortic stenosis1 trial
• Atrial fibrillation1 trial
• Coronary artery disease1 trial
• Familial hypercholesterolaemia1 trial
• Melanoma1 trial
• Type 1 diabetes1 trial

Phase

• Phase 32 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Boehringer Ingelheim1 trial
• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 trial
• Happitech BV1 trial
• Medtronic MiniMed, Inc.1 trial
• Pfizer1 trial
• and 2 more

Running trials

• Recruiting

  Detection of Atrial Fibrillation Using PPG From Smartphone Cameras

  NCT07779213· Happitech BV· Source

  Contact: Fleur van Haveren, Research Cardiology

• Recruiting

  Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347)

  NCT06739811· Medtronic MiniMed, Inc.· Source

  Contact: Peter Ruben van Dijk, Dr.

• Active, not recruiting

  Image Supported Lead Placement in CRT

  NCT05053568· UMC Utrecht· Source

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation1 recruiting
• Type 1 diabetes1 recruiting

Closed trials

• Completed

  Upper Extremity Versus Lower Extremity Accessory Access Sites During Transcatheter Aortic Valve Implantation

  NCT05672823· Radboud University Medical Center· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Pfizer· Source